Tasly Pharmaceutical Group Co., Ltd.
- Country
- 🇨🇳China
- Ownership
- Public, Subsidiary
- Established
- 1998-04-30
- Employees
- 9.2K
- Market Cap
- -
- Website
- https://www.taslypharma.com
Phase III Clinical Study on Efficacy y and Safety of Susu Zhike Granules for Treating Acute Cough Due to Common Cold With Cold-cough Syndrome in Children
- Conditions
- Cough
- Interventions
- Drug: High dose Susu Xiao'er Zhike GranulesDrug: Extremely-low dose Susu Xiao'er Zhike Granules
- First Posted Date
- 2025-01-14
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- Tasly Pharmaceutical Group Co., Ltd
- Target Recruit Count
- 360
- Registration Number
- NCT06773117
- Locations
- 🇨🇳
The First Teaching Hospital of Tianjin University of TCM, Tianjin, Tianjin, China
Efficacy and Safety of Changkang Granules in the Treatment of Irritable Bowel Syndrome With Predominant Diarrhea (Liver qi Affecting the Spleen Pattern)
- Conditions
- Diarrhea-predominant Irritable Boewl Syndrome
- Interventions
- Drug: Changkang Granules placebo
- First Posted Date
- 2024-12-31
- Last Posted Date
- 2024-12-31
- Lead Sponsor
- Tasly Pharmaceutical Group Co., Ltd
- Target Recruit Count
- 520
- Registration Number
- NCT06753890
- Locations
- 🇨🇳
Baoding First Traditional Chinese Medicine Hospital, Baoding, China
🇨🇳No. 5, Beixiange Street, Xuanwu District, Beijing, Beijing, China
🇨🇳The Second Affiliated Hospital of Hunan University of Chinese Medicine, Changsha, China
A Study of the Efficacy and Safety of Antiwei Granules in the Treatment of Common Cold
- Conditions
- Common Cold
- Interventions
- Drug: Antiwei Granules Placebo
- First Posted Date
- 2024-11-20
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Tasly Pharmaceutical Group Co., Ltd
- Target Recruit Count
- 480
- Registration Number
- NCT06697886
- Locations
- 🇨🇳
Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, China
🇨🇳changsha Hospital Affiliated to Hunan University, Changsha, China
🇨🇳Chengdu Pidu District Hospital of TCM, Chengdu, China
A Study of Lianxiaxiaopi Granules in the Treatment of Postprandial Distress Syndrome
- Conditions
- Postprandial Distress Syndrome
- Interventions
- Drug: Lianxiaxiaopi GranulesDrug: a simulated agent of Lianxiaxiaopi Granules
- First Posted Date
- 2024-11-20
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Tasly Pharmaceutical Group Co., Ltd
- Target Recruit Count
- 342
- Registration Number
- NCT06696261
- Locations
- 🇨🇳
Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, Beijing, China
🇨🇳Gansu Provincial Hospital of Traditional Chinese Medicine, Lanzhou, Gansu, China
🇨🇳The First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang, Guizhou, China
Efficacy and Safety of Xiangjurupining Capsule for Hyperplasia of Mammary Glands
- Conditions
- Hyperplasia of Mammary Glands
- Interventions
- Drug: Xiang Ju Ru Pi Ning capsule PlaceboDrug: Xiang Ju Ru Pi Ning capsule
- First Posted Date
- 2024-11-13
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Tasly Pharmaceutical Group Co., Ltd
- Target Recruit Count
- 430
- Registration Number
- NCT06685978
- Locations
- 🇨🇳
Xuzhou Central Hospital, Xuzhou, Jiangsu, China
🇨🇳Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, Beijing, China
🇨🇳East Hospital of Beijing University of Chinese Medicine, Beijing, Beijing, China
Efficacy and Safety of Jia Shen Tablets in Chronic Heart Failure
- Conditions
- Heart Failure
- Interventions
- Drug: Jia Shen Tablet PlaceboDrug: Low dose Jia Shen TabletDrug: High dose Jia Shen Tablet
- First Posted Date
- 2024-11-01
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Tasly Pharmaceutical Group Co., Ltd
- Target Recruit Count
- 288
- Registration Number
- NCT06669169
- Locations
- 🇨🇳
The First Affiliated Hospital of Tianjin University of traditional Chinese, Tianjin, Tianjin, China
Pharmacokinetic and Pharmacodynamic of Jia Shen Tablets in Chronic Heart Failure
- Conditions
- Heart Failure
- Interventions
- Drug: Jia Shen Tablet
- First Posted Date
- 2024-04-04
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- Tasly Pharmaceutical Group Co., Ltd
- Target Recruit Count
- 18
- Registration Number
- NCT06348498
- Locations
- 🇨🇳
The Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, Tianjin, China
A Study of the Effectiveness and Safety of JS1-1-01 in Patients With Moderate to Severe Depression
- Conditions
- Depression
- Interventions
- Drug: JS1-1-01 low-dose groupDrug: JS1-1-01 high-dose groupDrug: Placebo groupDrug: JS1-1-01 pills; JS1-1-01 placebo pills; Duloxetine hydrochloride placebo capsulesDrug: Active drug group
- First Posted Date
- 2024-02-14
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Tasly Pharmaceutical Group Co., Ltd
- Target Recruit Count
- 260
- Registration Number
- NCT06259526
- Locations
- 🇨🇳
Peking University Sixth Hospital, Peking, Beijing, China
🇨🇳Chongqing 11th People's Hospital, Chongqing, Chongqing, China
🇨🇳Hebei Provincial Mental Health Center, Baoding, Hebei, China
A Study of STRO-002 in Chinese Adults With Epithelial Ovarian Cancer and Other Advanced Malignant Solid Tumors
- Conditions
- Neoplasm Malignant
- Interventions
- Biological: STRO-002
- First Posted Date
- 2024-02-02
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- Tasly Pharmaceutical Group Co., Ltd
- Target Recruit Count
- 132
- Registration Number
- NCT06238687
- Locations
- 🇨🇳
West China Hospital of Sichuan University, Chengdu, Sichuan, China
A Study to Evaluate Efficacy and Safety of Qingzhu Granules in the Treatment of Acute Gouty Arthritis
- Conditions
- Gouty Arthritis
- Interventions
- Drug: Qingzhu Granules Placebo
- First Posted Date
- 2023-10-05
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- Tasly Pharmaceutical Group Co., Ltd
- Target Recruit Count
- 472
- Registration Number
- NCT06068478
- Locations
- 🇨🇳
Henan Province Luoyang Orthopedic Hospital, Luoyang, Henan, China
🇨🇳Xinxiang Central Hospital, Xinxiang, Henan, China
Zhengzhou People's Hospital